egfr Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions
Barbara Melosky, Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada
Curr. Oncol. 2012, 19(1), 8; https://doi.org/10.3747/co.19.955
Submission received: 3 November 2011
/
Revised: 5 December 2011
/
Accepted: 8 January 2012
/
Published: 1 February 2012
Excerpt
Note: In lieu of an abstract, this is an excerpt from the first page.
The systemic treatment options and algorithm for stage iv non-small-cell lung cancer have changed tremendously since 2005, leading to improved survival and quality of life for this group of patients [...]
Share and Cite
MDPI and ACS Style
Melosky, B. egfr Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions. Curr. Oncol. 2012, 19, 8. https://doi.org/10.3747/co.19.955
AMA Style
Melosky B. egfr Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions. Current Oncology. 2012; 19(1):8. https://doi.org/10.3747/co.19.955
Chicago/Turabian StyleMelosky, B. 2012. "egfr Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions" Current Oncology 19, no. 1: 8. https://doi.org/10.3747/co.19.955
